Alnylam Licenses RNAi Patent to RNAx

genomeweb
360dx

Alnylam Licenses RNAi Patent to RNAx

Jan 27, 2004

NEW YORK, Jan. 27 (GenomeWeb News) - Alnylam Pharmaceuticals, through its German affiliate, Ribopharma, has granted a license to its RNAi patent to Ribopharma, the company said today.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

Illumina Accelerator Program Adds Five Startups to Eighth Investment Cycle
Common Tuberculosis Lineage Spread With European Colonization, Analysis Indicates
Acute Myeloid Leukemia Analysis Brings Together Integrated 'Omic, Drug Response Profiles
Foundation Medicine, Novartis Partner to Develop CDx for Oncology Drugs
Roche Diagnostics' Revenues Grow 6 Percent in First Nine Months of 2018
Abbott Q3 Dx Business Grows 43 Percent

The Scan

Microsoft, But the Brain, Too

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

Been Reclassified

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

This Week in Cell

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

Pursuit of a Cancer Vaccine

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

Main menu